Hepatitis C in Israeli prisons: status report

Abstract The article discusses and analyzes the changes that have taken place since 2016 in Israeli policy with regard to the treatment, diagnosis and detection of hepatitis C (HCV) in prison settings. The article finds indications of promising changes to official procedure, such as the statement by...

Full description

Bibliographic Details
Main Authors: Niv Michaeli, Anat Litvin, Nadav Davidovitch
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Harm Reduction Journal
Subjects:
HCV
Online Access:http://link.springer.com/article/10.1186/s12954-020-00430-y
id doaj-57311aa8bf234d918b28e4c9e6e8ee6c
record_format Article
spelling doaj-57311aa8bf234d918b28e4c9e6e8ee6c2020-11-25T03:59:13ZengBMCHarm Reduction Journal1477-75172020-10-011711610.1186/s12954-020-00430-yHepatitis C in Israeli prisons: status reportNiv Michaeli0Anat Litvin1Nadav Davidovitch2Physicians for Human Rights IsraelPhysicians for Human Rights IsraelSchool of Public Health, Faculty of Health Sciences, Ben Gurion University of the NegevAbstract The article discusses and analyzes the changes that have taken place since 2016 in Israeli policy with regard to the treatment, diagnosis and detection of hepatitis C (HCV) in prison settings. The article finds indications of promising changes to official procedure, such as the statement by authorities that they plan to begin screening new inmates for HCV, and the increase in the number of inmates provided antiviral drugs. These measures, however, only came about after a prolonged campaign and legal battle by human rights organizations, patient advocacy groups and the medical community. Despite these encouraging changes, it appears that a significant portion of inmates in need of treatment are still not getting it due both to bureaucratic delays and to inmates’ reluctance. In addition, in the absence of a suitable screening program, the extant figures of morbidity—high in themselves—may reflect underdiagnosis. The flaws in the policymaking process and in its implementation may be attributed, at least in part, to the fact that the prison healthcare system is under the aegis of the Israel Prison Service and not that of a medical body. This reality places the medical staff in prisons in a state of dual loyalty, and also means the prison healthcare system is excluded from national health plans and major sources of budgeting, leaving it without sufficient means to provide the necessary level of care. These problems plague the prison healthcare system in general and are not limited to its handling of HCV. These challenges are not unique to Israel, and many other Western countries must also face the obstacles that are the result of prison healthcare services being subject to the authority of the correctional establishment. As this test case demonstrates, extended active involvement by civil organizations and the medical community are essential to promoting and ensuring inmates’ right to health.http://link.springer.com/article/10.1186/s12954-020-00430-yHCVPrisonIsraelHuman rights
collection DOAJ
language English
format Article
sources DOAJ
author Niv Michaeli
Anat Litvin
Nadav Davidovitch
spellingShingle Niv Michaeli
Anat Litvin
Nadav Davidovitch
Hepatitis C in Israeli prisons: status report
Harm Reduction Journal
HCV
Prison
Israel
Human rights
author_facet Niv Michaeli
Anat Litvin
Nadav Davidovitch
author_sort Niv Michaeli
title Hepatitis C in Israeli prisons: status report
title_short Hepatitis C in Israeli prisons: status report
title_full Hepatitis C in Israeli prisons: status report
title_fullStr Hepatitis C in Israeli prisons: status report
title_full_unstemmed Hepatitis C in Israeli prisons: status report
title_sort hepatitis c in israeli prisons: status report
publisher BMC
series Harm Reduction Journal
issn 1477-7517
publishDate 2020-10-01
description Abstract The article discusses and analyzes the changes that have taken place since 2016 in Israeli policy with regard to the treatment, diagnosis and detection of hepatitis C (HCV) in prison settings. The article finds indications of promising changes to official procedure, such as the statement by authorities that they plan to begin screening new inmates for HCV, and the increase in the number of inmates provided antiviral drugs. These measures, however, only came about after a prolonged campaign and legal battle by human rights organizations, patient advocacy groups and the medical community. Despite these encouraging changes, it appears that a significant portion of inmates in need of treatment are still not getting it due both to bureaucratic delays and to inmates’ reluctance. In addition, in the absence of a suitable screening program, the extant figures of morbidity—high in themselves—may reflect underdiagnosis. The flaws in the policymaking process and in its implementation may be attributed, at least in part, to the fact that the prison healthcare system is under the aegis of the Israel Prison Service and not that of a medical body. This reality places the medical staff in prisons in a state of dual loyalty, and also means the prison healthcare system is excluded from national health plans and major sources of budgeting, leaving it without sufficient means to provide the necessary level of care. These problems plague the prison healthcare system in general and are not limited to its handling of HCV. These challenges are not unique to Israel, and many other Western countries must also face the obstacles that are the result of prison healthcare services being subject to the authority of the correctional establishment. As this test case demonstrates, extended active involvement by civil organizations and the medical community are essential to promoting and ensuring inmates’ right to health.
topic HCV
Prison
Israel
Human rights
url http://link.springer.com/article/10.1186/s12954-020-00430-y
work_keys_str_mv AT nivmichaeli hepatitiscinisraeliprisonsstatusreport
AT anatlitvin hepatitiscinisraeliprisonsstatusreport
AT nadavdavidovitch hepatitiscinisraeliprisonsstatusreport
_version_ 1724455151259877376